Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nanoviricides Inc (NY: NNVC )

2.230 +0.430 (+23.89%)
Official Closing Price Updated: 8:00 PM EDT, May 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 604,081
Open 1.890
Bid (Size) 2.150 (7)
Ask (Size) 2.200 (1)
Prev. Close 1.800
Today's Range 1.860 - 2.290
52wk Range 1.000 - 2.290
Shares Outstanding 11,814,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
NNVC Stock Earnings: Nanoviricides Beats EPS for Q3 2024
NNVC stock results show that Nanoviricides beat analyst estimates for earnings per share the third quarter of 2024. 
Via InvestorPlace

Performance

YTD
+116.50%
+116.50%
1 Month
+88.98%
+88.98%
3 Month
+87.39%
+87.39%
6 Month
+96.01%
+96.01%
1 Year
+104.59%
+104.59%

More News

Read More
NanoViricides Has Filed its Quarterly Report
Via ACCESSWIRE
A Novel Broad-Spectrum Antiviral with Activity Against RSV
Via ACCESSWIRE
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City
Via ACCESSWIRE
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
Via ACCESSWIRE
A Novel Broad-Spectrum Antiviral with Activity Against Influenza A
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire
Via InvestorPlace
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
Via ACCESSWIRE
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
Via ACCESSWIRE
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
Via ACCESSWIRE
A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?
Via Benzinga
Exposures COVID-19
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
Via ACCESSWIRE
NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase™ 2024
Via Benzinga
NanoViricides to Present at the Biotech Showcase in San Fransisco
Via ACCESSWIRE
Is This Ticker That InvestorsObserver Expects To Soar By More Than 350% Next Year On Your Watchlist?
Via News Direct
Topics Death
Exposures COVID-19 Death
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
Via ACCESSWIRE
NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
Via ACCESSWIRE
Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
Via ACCESSWIRE
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
Via ACCESSWIRE
NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
Via ACCESSWIRE
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
Via Benzinga
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.